Concepts (252)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 25 | 2025 | 1194 | 4.610 |
Why?
|
| Phthalic Acids | 8 | 2022 | 36 | 4.440 |
Why?
|
| Postmenopause | 20 | 2025 | 237 | 4.320 |
Why?
|
| Environmental Pollutants | 8 | 2025 | 94 | 3.350 |
Why?
|
| Women's Health | 14 | 2022 | 369 | 2.450 |
Why?
|
| Antidepressive Agents | 5 | 2018 | 225 | 1.940 |
Why?
|
| Environmental Exposure | 8 | 2025 | 219 | 1.730 |
Why?
|
| Biomarkers | 9 | 2023 | 1388 | 1.720 |
Why?
|
| Breast | 6 | 2025 | 183 | 1.710 |
Why?
|
| Mammography | 11 | 2019 | 280 | 1.680 |
Why?
|
| Benzhydryl Compounds | 3 | 2018 | 51 | 1.500 |
Why?
|
| Phenols | 3 | 2018 | 78 | 1.480 |
Why?
|
| Endometrial Neoplasms | 5 | 2019 | 55 | 1.310 |
Why?
|
| Endocrine Disruptors | 2 | 2021 | 77 | 1.240 |
Why?
|
| Fluorocarbons | 2 | 2025 | 38 | 1.160 |
Why?
|
| Anti-Mullerian Hormone | 3 | 2022 | 66 | 1.100 |
Why?
|
| Prospective Studies | 25 | 2025 | 3263 | 1.090 |
Why?
|
| Mammary Glands, Human | 3 | 2025 | 56 | 1.090 |
Why?
|
| Female | 58 | 2025 | 32560 | 1.070 |
Why?
|
| Aged | 39 | 2025 | 14273 | 1.050 |
Why?
|
| Middle Aged | 44 | 2025 | 17390 | 1.040 |
Why?
|
| Risk Factors | 26 | 2025 | 5309 | 0.980 |
Why?
|
| Body Mass Index | 11 | 2025 | 864 | 0.940 |
Why?
|
| Case-Control Studies | 10 | 2022 | 1115 | 0.910 |
Why?
|
| Suicidal Ideation | 2 | 2023 | 116 | 0.890 |
Why?
|
| Bone Density | 3 | 2022 | 134 | 0.840 |
Why?
|
| Humans | 64 | 2025 | 62866 | 0.830 |
Why?
|
| Adiposity | 1 | 2023 | 83 | 0.770 |
Why?
|
| Sleep | 2 | 2016 | 226 | 0.720 |
Why?
|
| Depression | 3 | 2017 | 884 | 0.690 |
Why?
|
| Job Application | 2 | 2021 | 8 | 0.680 |
Why?
|
| Environmental Monitoring | 3 | 2016 | 145 | 0.670 |
Why?
|
| Suicide | 1 | 2022 | 126 | 0.660 |
Why?
|
| Osteoporotic Fractures | 3 | 2021 | 33 | 0.660 |
Why?
|
| Menopause | 5 | 2022 | 257 | 0.660 |
Why?
|
| Breast Carcinoma In Situ | 1 | 2019 | 3 | 0.650 |
Why?
|
| Hot Flashes | 3 | 2021 | 99 | 0.650 |
Why?
|
| Medical Oncology | 2 | 2021 | 66 | 0.640 |
Why?
|
| Longitudinal Studies | 7 | 2021 | 1252 | 0.640 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2019 | 46 | 0.630 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 166 | 0.620 |
Why?
|
| Psychotropic Drugs | 1 | 2019 | 81 | 0.620 |
Why?
|
| United States | 19 | 2019 | 7745 | 0.610 |
Why?
|
| Weight Gain | 2 | 2022 | 170 | 0.610 |
Why?
|
| Premenopause | 4 | 2022 | 60 | 0.600 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 2445 | 0.600 |
Why?
|
| Depressive Disorder | 2 | 2018 | 285 | 0.600 |
Why?
|
| Cross-Sectional Studies | 12 | 2022 | 2552 | 0.590 |
Why?
|
| Colorectal Neoplasms | 3 | 2018 | 280 | 0.580 |
Why?
|
| Vasomotor System | 1 | 2018 | 21 | 0.580 |
Why?
|
| Sweating | 1 | 2016 | 26 | 0.530 |
Why?
|
| Prolactin | 1 | 2016 | 40 | 0.510 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 144 | 0.500 |
Why?
|
| Body Composition | 1 | 2016 | 152 | 0.500 |
Why?
|
| Cancer Survivors | 1 | 2018 | 112 | 0.500 |
Why?
|
| Obesity | 6 | 2025 | 1230 | 0.500 |
Why?
|
| Negotiating | 1 | 2016 | 15 | 0.500 |
Why?
|
| Incidence | 8 | 2025 | 1373 | 0.500 |
Why?
|
| Coffee | 2 | 2015 | 19 | 0.490 |
Why?
|
| Metabolic Syndrome | 2 | 2019 | 142 | 0.480 |
Why?
|
| Adult | 20 | 2025 | 16668 | 0.480 |
Why?
|
| Personnel Selection | 1 | 2016 | 55 | 0.480 |
Why?
|
| Research Personnel | 1 | 2016 | 94 | 0.470 |
Why?
|
| Depressive Disorder, Major | 1 | 2017 | 254 | 0.470 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2016 | 158 | 0.460 |
Why?
|
| Interviews as Topic | 2 | 2016 | 506 | 0.440 |
Why?
|
| Intra-Abdominal Fat | 2 | 2025 | 34 | 0.430 |
Why?
|
| Proportional Hazards Models | 7 | 2019 | 729 | 0.400 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 661 | 0.390 |
Why?
|
| Cohort Studies | 9 | 2019 | 2549 | 0.380 |
Why?
|
| Melatonin | 3 | 2018 | 66 | 0.370 |
Why?
|
| Risk-Taking | 1 | 2012 | 162 | 0.370 |
Why?
|
| Caffeine | 1 | 2011 | 49 | 0.370 |
Why?
|
| Prognosis | 4 | 2018 | 1729 | 0.370 |
Why?
|
| Absorptiometry, Photon | 3 | 2025 | 76 | 0.360 |
Why?
|
| Densitometry | 1 | 2011 | 12 | 0.360 |
Why?
|
| Central Nervous System Stimulants | 1 | 2011 | 65 | 0.360 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2012 | 140 | 0.360 |
Why?
|
| Data Collection | 2 | 2019 | 384 | 0.350 |
Why?
|
| Creatinine | 2 | 2021 | 135 | 0.330 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 192 | 0.330 |
Why?
|
| Inflammation | 2 | 2021 | 1142 | 0.330 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2021 | 80 | 0.320 |
Why?
|
| Caregivers | 1 | 2012 | 268 | 0.310 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 315 | 0.310 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 832 | 0.300 |
Why?
|
| Osteoporosis | 2 | 2013 | 108 | 0.280 |
Why?
|
| Breast Feeding | 2 | 2021 | 149 | 0.280 |
Why?
|
| Recreation | 1 | 2007 | 21 | 0.270 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 205 | 0.270 |
Why?
|
| Community Pharmacy Services | 2 | 2019 | 13 | 0.260 |
Why?
|
| Hip Fractures | 1 | 2007 | 77 | 0.250 |
Why?
|
| Survivors | 1 | 2007 | 170 | 0.250 |
Why?
|
| Diet | 3 | 2015 | 523 | 0.250 |
Why?
|
| Nutrition Surveys | 2 | 2016 | 142 | 0.240 |
Why?
|
| Poverty | 2 | 2013 | 295 | 0.240 |
Why?
|
| Linear Models | 4 | 2015 | 409 | 0.230 |
Why?
|
| Health Education | 1 | 2006 | 188 | 0.230 |
Why?
|
| Odds Ratio | 4 | 2019 | 769 | 0.230 |
Why?
|
| Fetal Blood | 1 | 2025 | 73 | 0.230 |
Why?
|
| Rural Population | 1 | 2006 | 202 | 0.230 |
Why?
|
| Subcutaneous Fat | 1 | 2025 | 47 | 0.230 |
Why?
|
| Motor Activity | 1 | 2007 | 344 | 0.220 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 487 | 0.220 |
Why?
|
| Self Report | 2 | 2016 | 371 | 0.220 |
Why?
|
| Talc | 2 | 2014 | 5 | 0.220 |
Why?
|
| Risk Assessment | 7 | 2019 | 2045 | 0.210 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2018 | 755 | 0.210 |
Why?
|
| Autistic Disorder | 1 | 2025 | 149 | 0.190 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 5413 | 0.190 |
Why?
|
| Pregnancy | 5 | 2025 | 2326 | 0.190 |
Why?
|
| Health Promotion | 1 | 2006 | 492 | 0.190 |
Why?
|
| Femur Neck | 1 | 2021 | 11 | 0.180 |
Why?
|
| Pelvic Bones | 1 | 2021 | 16 | 0.180 |
Why?
|
| Autism Spectrum Disorder | 1 | 2025 | 180 | 0.180 |
Why?
|
| Parity | 1 | 2021 | 72 | 0.180 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2021 | 48 | 0.180 |
Why?
|
| Surveys and Questionnaires | 6 | 2015 | 2652 | 0.170 |
Why?
|
| Logistic Models | 3 | 2016 | 1275 | 0.170 |
Why?
|
| Pharmacists | 2 | 2019 | 124 | 0.170 |
Why?
|
| Culture | 2 | 2018 | 77 | 0.160 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 21 | 0.160 |
Why?
|
| Pharmacies | 1 | 2019 | 36 | 0.150 |
Why?
|
| Faculty, Medical | 1 | 2021 | 198 | 0.150 |
Why?
|
| Anthropometry | 2 | 2009 | 86 | 0.150 |
Why?
|
| Body Weight | 2 | 2011 | 377 | 0.150 |
Why?
|
| Women | 1 | 2018 | 44 | 0.150 |
Why?
|
| Mastectomy | 1 | 2018 | 58 | 0.150 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2018 | 231 | 0.140 |
Why?
|
| Young Adult | 4 | 2016 | 4656 | 0.140 |
Why?
|
| Ovariectomy | 1 | 2018 | 102 | 0.140 |
Why?
|
| Maternal Behavior | 1 | 2018 | 32 | 0.140 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2018 | 146 | 0.140 |
Why?
|
| Time Factors | 5 | 2018 | 3749 | 0.130 |
Why?
|
| Child | 3 | 2025 | 4478 | 0.130 |
Why?
|
| Adolescent | 5 | 2023 | 6197 | 0.130 |
Why?
|
| Hypertension | 2 | 2019 | 590 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2019 | 358 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 503 | 0.120 |
Why?
|
| Mortality | 1 | 2017 | 160 | 0.120 |
Why?
|
| Costs and Cost Analysis | 2 | 2007 | 102 | 0.120 |
Why?
|
| Adipose Tissue | 1 | 2018 | 296 | 0.120 |
Why?
|
| Risk | 1 | 2016 | 378 | 0.120 |
Why?
|
| Blood Pressure | 1 | 2018 | 514 | 0.120 |
Why?
|
| Tea | 1 | 2015 | 32 | 0.120 |
Why?
|
| Health Surveys | 1 | 2016 | 313 | 0.120 |
Why?
|
| Perineum | 1 | 2014 | 20 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 2147 | 0.110 |
Why?
|
| Folic Acid | 1 | 2014 | 41 | 0.110 |
Why?
|
| Fatty Acids, Essential | 1 | 2013 | 8 | 0.110 |
Why?
|
| Hypersensitivity | 1 | 2014 | 61 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2016 | 366 | 0.100 |
Why?
|
| Feeding Behavior | 1 | 2015 | 259 | 0.100 |
Why?
|
| Ovarian Neoplasms | 1 | 2014 | 144 | 0.100 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2013 | 6 | 0.100 |
Why?
|
| Health Services Accessibility | 3 | 2008 | 554 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 934 | 0.100 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2013 | 37 | 0.100 |
Why?
|
| Age Factors | 2 | 2014 | 1556 | 0.100 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2012 | 44 | 0.100 |
Why?
|
| Vaginal Smears | 1 | 2012 | 55 | 0.100 |
Why?
|
| Male | 7 | 2025 | 29546 | 0.100 |
Why?
|
| Time | 1 | 2012 | 30 | 0.100 |
Why?
|
| Fatty Acids | 1 | 2013 | 200 | 0.100 |
Why?
|
| Health Literacy | 1 | 2013 | 81 | 0.100 |
Why?
|
| Physical Examination | 1 | 2012 | 112 | 0.100 |
Why?
|
| Erythrocytes | 1 | 2013 | 149 | 0.090 |
Why?
|
| Diet Surveys | 1 | 2011 | 44 | 0.090 |
Why?
|
| Melanoma | 1 | 2015 | 331 | 0.090 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 462 | 0.090 |
Why?
|
| Smoking | 2 | 2007 | 864 | 0.090 |
Why?
|
| Waist-Hip Ratio | 1 | 2011 | 11 | 0.090 |
Why?
|
| Soybean Proteins | 1 | 2011 | 17 | 0.090 |
Why?
|
| Minority Groups | 2 | 2013 | 139 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 85 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 414 | 0.080 |
Why?
|
| North Carolina | 2 | 2007 | 70 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1640 | 0.080 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 166 | 0.080 |
Why?
|
| Asthma | 1 | 2014 | 433 | 0.080 |
Why?
|
| Interleukin-6 | 1 | 2010 | 320 | 0.080 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2008 | 17 | 0.080 |
Why?
|
| Hormone Replacement Therapy | 1 | 2008 | 28 | 0.080 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2008 | 84 | 0.070 |
Why?
|
| Medically Underserved Area | 1 | 2008 | 28 | 0.070 |
Why?
|
| Testosterone | 1 | 2008 | 119 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 727 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 140 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 613 | 0.070 |
Why?
|
| Estradiol | 1 | 2008 | 257 | 0.070 |
Why?
|
| Body Height | 1 | 2007 | 68 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2008 | 144 | 0.070 |
Why?
|
| Age Distribution | 1 | 2007 | 258 | 0.070 |
Why?
|
| Mass Screening | 2 | 2008 | 689 | 0.060 |
Why?
|
| Patient Selection | 1 | 2008 | 482 | 0.060 |
Why?
|
| Colonic Polyps | 1 | 2005 | 25 | 0.060 |
Why?
|
| Precancerous Conditions | 1 | 2005 | 70 | 0.060 |
Why?
|
| Singapore | 1 | 2025 | 14 | 0.060 |
Why?
|
| Survival Rate | 1 | 2007 | 843 | 0.060 |
Why?
|
| Insurance Coverage | 1 | 2005 | 100 | 0.060 |
Why?
|
| Breast Density | 2 | 2015 | 17 | 0.060 |
Why?
|
| Socioeconomic Factors | 1 | 2006 | 775 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2008 | 476 | 0.050 |
Why?
|
| Amygdala | 1 | 2023 | 83 | 0.050 |
Why?
|
| Pain | 1 | 2023 | 406 | 0.040 |
Why?
|
| Career Choice | 1 | 2021 | 128 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2019 | 45 | 0.040 |
Why?
|
| Dyslipidemias | 1 | 2019 | 37 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2011 | 6549 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2021 | 264 | 0.040 |
Why?
|
| Communication Barriers | 1 | 2018 | 62 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 222 | 0.030 |
Why?
|
| Diabetes, Gestational | 1 | 2018 | 141 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2006 | 5598 | 0.030 |
Why?
|
| Protective Factors | 1 | 2015 | 33 | 0.030 |
Why?
|
| Powders | 1 | 2014 | 20 | 0.030 |
Why?
|
| Vitamin B Complex | 1 | 2014 | 15 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 1366 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2014 | 57 | 0.030 |
Why?
|
| Maternal Exposure | 1 | 2014 | 41 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 1119 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2018 | 1348 | 0.030 |
Why?
|
| Minority Health | 1 | 2013 | 6 | 0.030 |
Why?
|
| Urban Health | 1 | 2013 | 40 | 0.030 |
Why?
|
| Cities | 1 | 2013 | 30 | 0.030 |
Why?
|
| Infant | 1 | 2018 | 1623 | 0.030 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2013 | 16 | 0.030 |
Why?
|
| Arachidonic Acid | 1 | 2013 | 34 | 0.030 |
Why?
|
| Docosahexaenoic Acids | 1 | 2013 | 31 | 0.030 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2014 | 157 | 0.020 |
Why?
|
| Urban Population | 1 | 2013 | 190 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 2013 | 123 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2014 | 233 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2011 | 7 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2011 | 11 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2011 | 161 | 0.020 |
Why?
|
| Community-Based Participatory Research | 1 | 2008 | 49 | 0.020 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2007 | 57 | 0.020 |
Why?
|
| Poverty Areas | 1 | 2007 | 15 | 0.020 |
Why?
|
| Indians, North American | 1 | 2007 | 29 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 272 | 0.020 |
Why?
|
| Smoking Prevention | 1 | 2007 | 163 | 0.020 |
Why?
|
| Rectal Neoplasms | 1 | 2007 | 104 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 416 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2007 | 220 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2005 | 34 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2005 | 87 | 0.020 |
Why?
|
| Adenoma | 1 | 2005 | 68 | 0.010 |
Why?
|
| Colonoscopy | 1 | 2005 | 97 | 0.010 |
Why?
|
| Perception | 1 | 2005 | 173 | 0.010 |
Why?
|
| Recurrence | 1 | 2005 | 636 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2007 | 551 | 0.010 |
Why?
|